A 16-year multi-institutional study of the role of age and EBV status on PTLD incidence among pediatric heart transplant recipients

American Journal of Transplantation

Volumn 12, Issue 11, 2012, Pages 3061-3068

  Chinnock, R ^a   Webber, S A ^b   Dipchand, A I ^c   Brown, R N ^d   George, J F ^d  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d University of Alabama at Birmingham   (United States)

Author keywords

EBV; hazard; lymphoma; outcomes; PTLD

Indexed keywords

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; GROUPS BY AGE; HEART GRAFT; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MALE; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEROLOGY;

ADOLESCENT; AGE DISTRIBUTION; AGE FACTORS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LYMPHOPROLIFERATIVE DISORDERS; MALE; POSTOPERATIVE COMPLICATIONS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84868211024     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04197.x     Document Type: Article

References (31)

1. Zangwill SD, Hsu DT, Kichuk MR, et al., Incidence and outcome of primary Epstein-Barr virus infection and lymphoproliferative disease in pediatric heart transplant recipients. J Heart Lung Transpl 1998; 17: 1161-1166.
2. Schubert S, Abdul-Khaliq H, Lehmkuhl HB, et al., Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transpl 2009; 13: 54-62.
3. Katz BZ, Pahl E, Crawford SE, et al., Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort. Pediatr Transpl 2007; 11: 58-65.
4. Harwood JS, Gould FK, McMaster A, et al., Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation. Pediatr Transpl 1999; 3: 100-103.
5. Boyle GJ, Michaels MG, Webber SA, et al., Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. J Pediatr 1997; 131: 309-313.
6. Dharnidharka VR, Tejani AH, Ho PL, Harmon WE,. Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk. Am J Transplant 2002; 2: 993-998.
7. Webber SA, Naftel DC, Fricker FJ, et al., Lymphoproliferative disorders after paediatric heart transplantation: A multi-institutional study. The Lancet 2006; 367: 233-239.
8. Ho M, Miller G, Atchison RW, et al., Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis 1985; 152: 876-886.
9. Saemundsen AK, Klein G, Cleary M, Warnke R,. Epstein-Barr-virus-carrying lymphoma in cardiac transplant recipient. Lancet 1982; 2: 158.
10. Dummer JS, Bound LM, Singh G, Atchison RW, Kapadia SB, Ho M,. Epstein-Barr virus-induced lymphoma in a cardiac transplant recipient. Am J Med 1984; 77: 179-184.
11. Walker RC, Marshall WF, Strickler JG, et al., Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346-1353.
12. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al., Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: A cyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913-918.
13. Manlhiot C, Pollock-Barziv SM, Holmes C, et al., Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients. J Heart Lung Transpl 2010; 29: 648-657.
14. Hsu DT, Naftel DC, Webber SA, et al., Lessons learned from the pediatric heart transplant study. Congenit Heart Dis 2006; 1: 54-62.
15. Blackstone EH, Naftel DC, Turner ME,. The decomposition of time-varying hazard into phases, each incorporating a separate stream of concomitant information. J Am Statistical Assoc 1986; 81: 615-324.
16. Opelz G, Daniel V, Naujokat C, Dohler B,. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation 2009; 88: 962-967.
17. George JF, Pamboukian SV, Tallaj JA, et al., Balancing rejection and infection with respect to age, race, and gender: Clues acquired from 17 years of cardiac transplantation data. J Heart Lung Transpl 2010; 29: 966-972.
18. George JF, Taylor DO, Blume ED, et al., Minimizing infection and rejection death: Clues acquired from 19 years of multi-institutional cardiac transplantation data. J Heart Lung Transplant 2011; 30: 151-157.
19. Kirklin JK, Naftel DC, Bourge RC, et al., Evolving trends in risk profiles and causes of death after heart transplantation: A ten-year multi-institutional study. J Thorac Cardiovasc Surg 2003; 125: 881-890.
20. Blackstone EH, Kirklin JW,. Death and other time-related events after valve replacement. Circulation 1985; 72: 753-767.
21. Lim WH, Russ GR, Coates PT,. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology 2006; 11: 355-366.
22. Nadal D, Guzman J, Frohlich S, Braun DG,. Human immunoglobulin preparations suppress the occurrence of Epstein-Barr virus-associated lymphoproliferation. Exp Hematol 1997; 25: 223-231.
23. Abedi MR, Christensson B, al-Masud S, Hammarstrom L, Smith CI,. Gamma-globulin modulates growth of EBV-derived B-cell tumors in SCID mice reconstituted with human lymphocytes. Int J Cancer 1993; 55: 824-829.
24. Riddler SA, Breinig MC, McKnight JL,. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972-984.
25. Green M, Reyes J, Webber S, Rowe D,. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001; 3: 97-103.
26. Green M, Michaels MG, Katz BZ, et al., CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients. Am J Transplant 2006; 6: 1906-1912.
27. Haque T, Thomas JA, Falk KI, et al., Transmission of donor Epstein-Barr virus (EBV) in transplanted organs causes lymphoproliferative disease in EBV-seronegative recipients. J Gen Virol 1996; 77 (Pt 6): 1169-1172.
28. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT,. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. ProcNatl Acad Sci USA 1984; 81: 4510-4514.
29. Kirk R, Edwards LB, Kucheryavaya AY, et al., The Registry of the International Society for Heart and Lung Transplantation: Thirteenth official pediatric heart transplantation report-2010. J Heart Lung Transplant 2010; 29: 1119-1128.
30. Benden C, Aurora P, Burch M, et al., Monitoring of Epstein-Barr viral load in pediatric heart and lung transplant recipients by real-time polymerase chain reaction. J Heart Lung Transplant 2005; 24: 2103-2108.
31. Schubert S, Renner C, Hammer M, et al., Relationship of immunosuppression to Epstein-Barr viral load and lymphoproliferative disease in pediatric heart transplant patients. J Heart Lung Transplant 2008; 27: 100-105.